Publications by authors named "A Asad"

Background: Chlamydia is the most diagnosed bacterial sexually transmitted infection in England, but opportunistic testing remains low in general practice despite high prevalence among young people. Attempts to increase testing have been met with little success; therefore, there is a need to explore why rates remain low and how this may be improved.

Aim: To explore general practice staff perceptions of opportunistic chlamydia testing, including barriers, facilitators, interventions, and policies, using the Behaviour Change Wheel (BCW).

View Article and Find Full Text PDF

Context: The use of prebiotics and probiotics as a treatment for psychiatric conditions has gained interest due to their potential to modulate the gut-brain axis. This review aims to assess the effectiveness of these interventions in reducing symptoms of depression and anxiety in psychiatric populations.

Objective: The aim was to comprehensively review and appraise the effectiveness of prebiotic, probiotic, and synbiotic interventions in reducing clinical depression and anxiety symptoms.

View Article and Find Full Text PDF

Multi-drug resistance (MDR) in continues to pose a significant public health challenge, particularly in developing countries. Recent advances in genomics strengthen the surveillance of MDR-pathogens and antimicrobial resistance (AMR) mediators. However, genome-based investigations into resistome dynamics in are limited, specifically in Bangladesh.

View Article and Find Full Text PDF

Myofibroma is a rare mesenchymal tumor typically observed in children, with only a few reported cases in adults. It can be easily mistaken for more common benign lesions, making it essential to include them in the differential diagnosis of soft tissue masses. This case report presents a rare instance of myofibroma in a young adult, and a comprehensive review of the literature presenting case reports and case series of myofibroma cases in the head and neck regions of adult patients aged > 18 years.

View Article and Find Full Text PDF

Melanoma, a malignancy originating from melanocytes, poses a significant global health challenge, with approximately 325,000 cases and 57,000 deaths annually. Advanced melanoma (AM), categorized as stage III and IV, presents considerable treatment challenges due to its complex mutational landscape. Traditional treatment options have included checkpoint inhibitors and BRAF inhibitors, with pembrolizumab emerging as a promising agent.

View Article and Find Full Text PDF